LCZ-696(SACUBITRIL+VALSARTAN)
Chemical Name | LCZ-696(Sacubitril+Valsartan) | |
CAS Number Molecular Formula Molecular Weight | 936623-90-4 2(C24H29N5O3).2(C24H29NO5).5(H2O).6Na 1922.06 | |
Molecular Structure | ||
Packing | As customer’s requirements | |
Storage | Store in a tightly sealed container away from heat and direct light, and in a cool dry place. | |
Usage |
LCZ696 (sacubitril/Valsartan) is a combination drug for use in heart failure developed by Novartis. It consists of valsartan and sacubitril, in a 1:1 mixture by molecule count.
SPECIFICATION
Items | Specification |
Appearance | Off-white to white powder |
Water | Between 4.0% to 5.9% |
Isomers | XST-A: ≤0.5% |
LCZ-Q: ≤0.1% | |
LCZ-R: ≤0.1% | |
LCZ-S: ≤0.1% | |
Related Substances | LCZ-A≤1.2% |
Any unknown impurity:≤0.10% | |
Total impurities: ≤1.5% | |
Residue Solvents | Ethanol: ≤0.5% |
Ethyl ester: ≤0.5% | |
Butanone≤0.5% | |
Acetone≤0.5% | |
Triethylamine: ≤0.032% | |
N-hexane: ≤0.029% | |
Assay | Valsartan 49.8%~52.4% |
AHU377 47.1%~49.6% | |
LCZ696 97.0%~102.0% |